- Home
- LPG vs ELVN Comparison
LPG vs ELVN Comparison
Compare LPG & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPG
- ELVN
- Stock Information
- Founded
- LPG 2013
- ELVN 2016
- Country
- LPG United States
- ELVN United States
- Employees
- LPG N/A
- ELVN N/A
- Industry
- LPG Marine Transportation
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- LPG Consumer Discretionary
- ELVN Health Care
- Exchange
- LPG Nasdaq
- ELVN Nasdaq
- Market Cap
- LPG 990.5M
- ELVN 1.1B
- IPO Year
- LPG 2014
- ELVN 2020
- Fundamental
- Price
- LPG $25.19
- ELVN $21.47
- Analyst Decision
- LPG Buy
- ELVN Strong Buy
- Analyst Count
- LPG 2
- ELVN 5
- Target Price
- LPG $43.00
- ELVN $37.80
- AVG Volume (30 Days)
- LPG 772.9K
- ELVN 246.0K
- Earning Date
- LPG 01-30-2025
- ELVN 03-13-2025
- Dividend Yield
- LPG 15.87%
- ELVN N/A
- EPS Growth
- LPG N/A
- ELVN N/A
- EPS
- LPG 5.82
- ELVN N/A
- Revenue
- LPG $498,825,986.00
- ELVN N/A
- Revenue This Year
- LPG N/A
- ELVN N/A
- Revenue Next Year
- LPG N/A
- ELVN N/A
- P/E Ratio
- LPG $4.33
- ELVN N/A
- Revenue Growth
- LPG 1.76
- ELVN N/A
- 52 Week Low
- LPG $22.46
- ELVN $10.90
- 52 Week High
- LPG $51.66
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- LPG 50.05
- ELVN 42.14
- Support Level
- LPG $24.22
- ELVN $20.16
- Resistance Level
- LPG $27.53
- ELVN $23.08
- Average True Range (ATR)
- LPG 0.87
- ELVN 1.60
- MACD
- LPG 0.21
- ELVN -0.09
- Stochastic Oscillator
- LPG 40.33
- ELVN 25.14
About LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.